Dr. Pal on next steps with cabozantinib/atezolizumab in bladder cancer
Sumanta K. Pal, MD, City of Hope Comprehensive Cancer Center, discusses next steps for the combination of cabozantinib (Cabometyx) and atezolizumab (Tecentriq) in patients with bladder cancer. At the 2022 ASCO Annual Meeting Pal shared results from the phase 1b COSMIC-021 trial showing promising activity in patients with urothelial carcinoma who had no prior systemic therapy and were cisplatin ineligible; had no prior systemic therapy but were cisplatin eligible, or had received 1 prior immune checkpoint inhibitor, were VEGFR-TKI–naïve, and had received ≤2 lines of therapy overall.
Trial launches of MAT2A inhibitor plus sacituzumab govitecan in bladder cancer
June 26th 2024“The MAT2A-Trop2 ADC combination targets 2 distinct, yet complementary nodes in patients with MTAP-deleted urothelial cancer and has first-in-class potential to improve clinical outcomes for bladder cancer patients with poor prognosis associated with MTAP-deletion," says Darrin M. Beaupre, MD, PhD.
Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app
December 7th 2021“It's not a replacement for clinical judgment, obviously. But at the end of the day, the idea is that it shows you what your next steps are based on what the American Urological Association and [Society of Urologic Oncology] guidelines are for non-muscle invasive bladder cancer,” Chad R. Ritch, MD, MBA, FACS.
